Thamer Sliwa

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Lisa Pleyer, Sonja Burgstaller, Michael Girschikofsky et al. · Annals of Hematology · 2014 · 96 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

Lisa Pleyer, Ulrich Germing, Wolfgang R. Sperr et al. · Leukemia Research · 2014 · 66 citations

Medicine, Pharmacology, Pharmacotherapy +8

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

Georg Jeryczynski, Jürgen Thiele, Bettina Gisslinger et al. · American Journal of Hematology · 2017 · 65 citations · Full text

Medicine, Hematology, Pathology +16

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional study

Jakob M. Riedl, Florian Posch, Gerald W. Prager et al. · Therapeutic Advances in Medical Oncology · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacology +16

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller et al. · Journal of Hematology & Oncology · 2013 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9